Jennifer Chow

Company: iCell Gene Therapeutics

Job title: CEO

Bio:

Jennifer Chow is a pioneer in cell therapy, having led the launch of over 10 oncology therapeutics, including key CAR T cell therapies like Ide-cel, Liso-cel, Axi-cel, and Brexu-cel. She held leadership roles at Celgene, Kite (Gilead), and served as CEO of Chimeric Therapeutics. Now at iCell Gene Therapeutics, she is advancing innovative cell therapies for autoimmune diseases and cancer to address critical patient needs.

Seminars:

Demonstrating Durable Remission in Lupus with iCell Gene Therapeutics’ Dual-Target, Armored CAR-T Therapy 3:30 pm

Introducing iCell Gene Therapeutics’ ICG318 CD-19—BCMA/IL-15 compound CAR-T Evaluate the synergistic impact of combined B-cell and plasma cell depletion in enhancing durability of response Highlight iCell Gene Therapeutics’ 5+ year long-term follow-up data, to define what therapeutic durability looks like in lupus patientsRead more

day: Conference Day One P3

Industry Leaders Fireside Chat: What’s Happened in the Last Year & Where is the Field Headed Next? 8:40 am

Examining the evolution of the autoimmune cell therapy field over the last year Discussing progress across autologous, allogeneic, NK and in vivo modalities to uncover development strategies Considering indication selection strategies and the potential for indication diversification beyond lupus Exploring the future of the field to effectively scale and commercialise safe, durable therapiesRead more

day: Conference Day 1 P1